The study, sponsored by Charles University, aims to evaluate the transition from an open-source automated insulin delivery system (AndroidAPS) to commercially available systems (Control-IQ and MiniMed 780G) in adults with Type 1 Diabetes. This research is significant as it addresses the growing market for automated insulin delivery systems, which is projected to expand due to increasing diabetes prevalence and advancements in diabetes technology. The competitive landscape includes established players like Tandem Diabetes and Medtronic, which may face challenges from emerging technologies and open-source solutions. The findings could influence market dynamics, particularly in terms of user preferences and clinical outcomes, potentially impacting pricing strategies and market share.